Viking Therapeutics plans to advance oral obesity drug to late-stage trial-March 2024-www.financetom.com

Viking Therapeutics plans to advance oral obesity drug to late-stage trial

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Viking Therapeutics plans to advance oral obesity drug to late-stage trial

Mar 11, 2026 3:48 AM

Feb 11 (Reuters) - Viking ‌Therapeutics ⁠said on

Wednesday ⁠that ‌it ‌plans to ‌test its experimental oral ‌obesity

drug in a ⁠late-stage ⁠study ⁠later ‌this ‌year.

(Reporting ⁠by Sneha S K; Editing by ‌Sriraj Kalluvila)

Previous page： Perplexity AI to launch ads on search platform by fourth quarter Next page： --Bill Holdings Plans Targeted Investments in Fiscal 2025 to Accelerate 'Strategic' Priorities, Capture Large Market Opportunity

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Perplexity AI to launch ads on search platform by fourth quarter

Aug 25, 2024

(Reuters) - Nvidia ( NVDA ) and Jeff Bezos-backed Perplexity AI said on Thursday that it plans to introduce advertising on its artificial intelligence-powered search platform by the fourth quarter. Last month, the AI startup launched a program for publishers with an initial batch of partners, including TIME, Der Spiegel, and Fortune, in which it plans to share revenue from...

--Bill Holdings Plans Targeted Investments in Fiscal 2025 to Accelerate 'Strategic' Priorities, Capture Large Market Opportunity

Aug 25, 2024

04:50 PM EDT, 08/22/2024 (MT Newswires) -- Price: 52.47, Change: +1.73, Percent Change: +3.41 ...

MoneyHero Makes $8 Million Non-Binding Offer to Acquire Rival MoneySmart

Aug 25, 2024

03:02 PM EDT, 08/22/2024 (MT Newswires) -- MoneyHero ( MNY ) said Thursday it made a non-binding offer to purchase 100% of the shares of its rival, MoneySmart, for $8 million, with potential valuation upside. The deal involves issuing new MoneyHero ( MNY ) shares, with additional valuation to be paid in cash based on the results of due diligence,...

Nestle to keep Health Science unit after CEO's exit, chairman tells paper

Aug 25, 2024

(Widens distribution.) ZURICH, Aug 25 (Reuters) - Nestle intends to keep its Health Science unit, Chairman Paul Bulcke said in a newspaper interview published on Sunday, after the food giant announced it was replacing its CEO Mark Schneider with company veteran Laurent Freixe. The health business is among the Nestle units which some analysts say could be sold over the...